Artery injection to improve prostate cancer drug delivery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether injecting a drug directly into the artery that feeds the prostate can deliver more of it to the tumor, potentially making treatment more effective. It is for men with high-risk prostate cancer that has not spread and who are scheduled for surgery to remove the prostate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult male with prostate cancer that is high-risk and has not spread to distant parts of the body.
- You have not had previous treatments like radiation or hormone therapy for prostate cancer.
- You are scheduled for surgery to remove your prostate (radical prostatectomy).
- Your prostate cancer shows high uptake on a special PET scan (PSMA PET/CT).
- Your blood counts and blood chemistry are within normal ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
This trial tests a new way to plan radiation for high-risk prostate cancer. Doctors will use a special PET scan (PSMA PET) to find the main tumor inside the prostate and give it a stronger dose of radiation, along with standard hormone therapy. This approach might improve outcomes for patients with aggressive disease.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
This study looks at how well two different PSMA PET scans work for men with advanced prostate cancer. The scans help doctors see where the cancer is, which can guide treatment decisions and help you and your doctor plan next steps.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.